OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY
Clinical trials for OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY explained in plain language.
Never miss a new study
Get alerted when new OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY trials appear
Sign up with your email to follow new studies for OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New heart drug shows promise in chinese patients with thick heart muscle
Disease control CompletedThis study looked at the long-term safety of a drug called aficamten in 40 Chinese patients with a heart condition that makes the heart muscle too thick and blocks blood flow. Patients who had already been in a previous study took aficamten for up to several months. The main goal…
Matched conditions: OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY
Phase: PHASE3 • Sponsor: Corxel Pharmaceuticals • Aim: Disease control
Last updated May 17, 2026 06:50 UTC
-
Heart drug mavacamten tested for Long-Term safety in 314 patients
Disease control CompletedThis study looked at the long-term safety of the drug mavacamten in 314 adults with hypertrophic cardiomyopathy, a condition where the heart muscle thickens. Participants had already completed earlier studies of the drug. The main goal was to track side effects over time, not to …
Matched conditions: OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY
Phase: PHASE2, PHASE3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated May 17, 2026 06:49 UTC